Mega Lifesciences PCL (BKK:MEGA)
Thailand
· Delayed Price · Currency is THB 28.25
+0.75 (2.73%)
Apr 25, 2025, 11:30 AM ICT
Mega Lifesciences PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 15,344 | 15,681 | 15,686 | 14,136 | 12,589 | Upgrade
|
| Other Revenue | 41.09 | 34.41 | 40.64 | 36.67 | 23.61 | Upgrade
|
| Revenue | 15,385 | 15,716 | 15,727 | 14,172 | 12,613 | Upgrade
|
| Revenue Growth (YoY) | -2.10% | -0.07% | 10.97% | 12.36% | 12.98% | Upgrade
|
| Cost of Revenue | 7,590 | 8,586 | 8,647 | 8,225 | 7,603 | Upgrade
|
| Gross Profit | 7,796 | 7,130 | 7,080 | 5,947 | 5,010 | Upgrade
|
| Selling, General & Admin | 4,385 | 4,191 | 4,359 | 3,769 | 3,288 | Upgrade
|
| Operating Expenses | 4,385 | 4,191 | 4,359 | 3,769 | 3,288 | Upgrade
|
| Operating Income | 3,411 | 2,939 | 2,722 | 2,178 | 1,722 | Upgrade
|
| Interest Expense | -38.49 | -31.25 | -28.73 | -28.28 | -72.28 | Upgrade
|
| Interest & Investment Income | 61.74 | 60.69 | 39.82 | 10.03 | 11.94 | Upgrade
|
| Earnings From Equity Investments | 0.15 | 0.07 | 0.18 | -1.51 | -45.52 | Upgrade
|
| Currency Exchange Gain (Loss) | -1,082 | -706.57 | -138.16 | 118.52 | 18.11 | Upgrade
|
| EBT Excluding Unusual Items | 2,352 | 2,262 | 2,595 | 2,277 | 1,634 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -11.7 | Upgrade
|
| Pretax Income | 2,352 | 2,262 | 2,595 | 2,277 | 1,623 | Upgrade
|
| Income Tax Expense | 339.63 | 269.06 | 354.63 | 336.02 | 234.33 | Upgrade
|
| Earnings From Continuing Operations | 2,013 | 1,993 | 2,240 | 1,941 | 1,388 | Upgrade
|
| Minority Interest in Earnings | -0.07 | 0.05 | 1.49 | 5.97 | 4.2 | Upgrade
|
| Net Income | 2,012 | 1,993 | 2,242 | 1,947 | 1,393 | Upgrade
|
| Net Income to Common | 2,012 | 1,993 | 2,242 | 1,947 | 1,393 | Upgrade
|
| Net Income Growth | 0.99% | -11.10% | 15.14% | 39.79% | 22.32% | Upgrade
|
| Shares Outstanding (Basic) | 872 | 872 | 872 | 872 | 872 | Upgrade
|
| Shares Outstanding (Diluted) | 872 | 872 | 872 | 872 | 872 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | 0.12% | Upgrade
|
| EPS (Basic) | 2.31 | 2.29 | 2.57 | 2.23 | 1.60 | Upgrade
|
| EPS (Diluted) | 2.31 | 2.29 | 2.57 | 2.23 | 1.60 | Upgrade
|
| EPS Growth | 0.99% | -11.10% | 15.14% | 39.79% | 22.18% | Upgrade
|
| Free Cash Flow | 2,154 | 1,652 | 1,692 | 2,575 | 1,395 | Upgrade
|
| Free Cash Flow Per Share | 2.47 | 1.90 | 1.94 | 2.95 | 1.60 | Upgrade
|
| Dividend Per Share | 1.600 | 1.600 | 1.600 | 1.380 | 0.900 | Upgrade
|
| Dividend Growth | - | - | 15.94% | 53.33% | 25.00% | Upgrade
|
| Gross Margin | 50.67% | 45.37% | 45.02% | 41.97% | 39.72% | Upgrade
|
| Operating Margin | 22.17% | 18.70% | 17.30% | 15.37% | 13.65% | Upgrade
|
| Profit Margin | 13.08% | 12.68% | 14.25% | 13.74% | 11.04% | Upgrade
|
| Free Cash Flow Margin | 14.00% | 10.51% | 10.76% | 18.17% | 11.06% | Upgrade
|
| EBITDA | 3,614 | 3,146 | 2,917 | 2,378 | 1,909 | Upgrade
|
| EBITDA Margin | 23.49% | 20.02% | 18.55% | 16.78% | 15.14% | Upgrade
|
| D&A For EBITDA | 202.84 | 207.49 | 195.24 | 200.2 | 187.09 | Upgrade
|
| EBIT | 3,411 | 2,939 | 2,722 | 2,178 | 1,722 | Upgrade
|
| EBIT Margin | 22.17% | 18.70% | 17.30% | 15.37% | 13.65% | Upgrade
|
| Effective Tax Rate | 14.44% | 11.90% | 13.67% | 14.76% | 14.44% | Upgrade
|
| Revenue as Reported | 15,447 | 15,776 | 15,767 | 14,301 | 12,643 | Upgrade
|
| Advertising Expenses | 1,232 | 1,323 | 1,266 | 1,052 | 930.15 | Upgrade
|
Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.